When headlines create fear, women deserve the whole story—not another reason to suffer in silence.
Michelle Sandwisch, ARNP | Origin Medicine | November 2026
________________________________________________________________________________________
In October 2026, headlines suggesting that testosterone therapy could increase cardiovascular risk eightfold in postmenopausal women understandably created alarm.
For women who have experienced meaningful, sometimes life-changing improvements with hormone therapy, these headlines can be frightening.
As a healthcare provider who works closely with women navigating hormonal changes, I find this particularly concerning.
I have witnessed women who have spent years struggling with exhaustion, declining sexual desire, changes in body composition, diminished motivation, and a profound sense that they no longer feel like themselves.
For some, individualized hormone therapy has been transformative. They describe feeling stronger, more energetic, more connected to their partners, and more like the women they remember being.
These clinical experiences matter. They do not replace controlled research, but they should inspire us to investigate why some women respond so meaningfully to treatment.
Women’s symptoms deserve to be taken seriously, and so do the treatments that may improve their quality of life.
Yet women’s hormonal health continues to face a troubling disparity: limited research, inadequate treatment options, and a tendency to interpret emerging evidence through headlines that may create more fear than understanding.
For those of us who remember the controversy surrounding the Women’s Health Initiative in 2002, the situation feels familiar.
Are we repeating history?
An Eightfold Cardiovascular Risk? Let’s Examine the Evidence.
The recent study presented at The Menopause Society’s annual meeting used the TriNetX electronic health record database to compare postmenopausal women identified as initiating testosterone therapy with women who had no documented testosterone exposure.
The investigators reported cardiovascular outcomes in approximately 3.8% of women in the testosterone group compared with 0.5% in the comparison group.
The reported hazard ratio was approximately 8.
At first glance, that sounds extraordinary.
But extraordinary findings deserve particularly careful examination.
The study was retrospective, meaning researchers examined existing medical records rather than conducting a randomized clinical trial.
More importantly, the publicly available findings leave fundamental questions unanswered.
The researchers did not establish several critical aspects of testosterone exposure:
· Whether women actually received and used the prescribed testosterone.
· What doses and formulations were administered.
· Whether treatment involved creams, injections, or implanted pellets.
· What testosterone concentrations women achieved.
· Whether higher testosterone concentrations were associated with greater cardiovascular risk.
· Whether the reported cardiovascular outcomes represented independently confirmed events or diagnostic codes.
These are not minor omissions.
They are central to understanding whether testosterone itself contributed to the reported outcomes.
A prescription recorded in an electronic database does not confirm that a woman received the medication, used it consistently, or continued treatment for years.
Without knowing the actual exposure, it becomes extremely difficult to attribute an outcome to a specific hormone, dose, or treatment approach.
The study identified an association. It did not establish that testosterone caused cardiovascular disease.
Could Differences in Medical Care Explain Some of the Findings?
Another concern involves what researchers call surveillance bias.
Women receiving testosterone therapy are often engaged in ongoing healthcare. On the other hand, those that get their testosterone from questionable sourcing often do not get adequate surveillance and health care.
Those that do receive testosterone from clinicians, may have more frequent appointments, laboratory testing, medication reviews, and opportunities for medical diagnoses to be documented.
Women in the comparison group may have less frequent contact with the healthcare system but this is unknown.
Differences can influence the number of diagnoses appearing in electronic medical records.
The study’s cardiovascular outcome combined serious events, such as myocardial infarction and ischemic stroke, with diagnoses including angina, chronic ischemic heart disease, and heart failure.
These outcomes are clinically important, but they are not interchangeable.
Additionally, a diagnostic code entered during a cardiovascular evaluation does not necessarily establish that a woman experienced a heart attack or stroke.
The publicly available results did not adequately separate the individual components of the combined outcome.
The comparison group experienced an unusually low reported cardiovascular event rate.
That raises questions about whether the two groups had comparable follow-up, whether events occurring outside participating healthcare systems were captured, and whether important differences remained despite statistical matching.
These limitations do not prove the study’s findings are incorrect.
They do mean that the reported eightfold association should not be interpreted as an established eightfold increase in cardiovascular harm caused by testosterone.
What Does the Existing Research Actually Show?
This is where I believe the conversation needs greater balance.
When a new study produces a dramatic result, we should compare it with the broader body of evidence.
Several randomized trials of testosterone therapy in women have evaluated treatment using documented doses.
A 2019 systematic review and meta-analysis included 36 randomized controlled trials involving approximately 8,480 women.
The investigators found that nonoral testosterone did not significantly worsen lipid profiles, although acne and hair growth were more common.
Importantly, the trials did not identify a clear increase in serious adverse events during the study periods.
That is reassuring, but most trials were relatively short and were not sufficiently powered to establish long-term cardiovascular safety.
The BLISS Study: An Important Piece of the Conversation
The BioSante LibiGel Safety Study, known as BLISS, was designed to evaluate cardiovascular and breast safety in postmenopausal women receiving testosterone gel.
The study enrolled approximately 3,656 women aged 50 and older with cardiovascular risk factors.
More than 7,300 woman-years of observation were accumulated.
Sponsor-reported findings described fewer cardiovascular events than anticipated.
This is important because the study included women with elevated baseline cardiovascular risk rather than exclusively healthy participants.
However, the complete trial results were never published in a peer-reviewed journal, and cardiovascular event counts separated by treatment group were not publicly released.
Therefore, we cannot calculate a reliable testosterone-versus-placebo cardiovascular risk estimate from those reports.
Still, the available findings provide context that deserves discussion when evaluating an observational study reporting an unusually large cardiovascular association.
What About Women Receiving Testosterone Pellets?
Another relevant body of research involves prospective observational studies of women receiving subcutaneous testosterone implants.
Investigations by Glaser and colleagues documented administered doses, measured serum testosterone concentrations, and followed women over time.
Some participants achieved testosterone concentrations substantially above conventional female reference ranges.
These cohorts reported relatively few adverse events attributed to testosterone beyond expected androgenic effects.
This is particularly relevant to the recent database study because actual testosterone administration and measured concentrations were documented.
However, these were not randomized cardiovascular safety trials. Their design, adverse-event ascertainment, and limited ability to detect uncommon outcomes mean they cannot establish that higher-dose testosterone is cardiovascularly safe.
What they do demonstrate is that the existing literature is more complex than a single alarming headline suggests.
What About the Large Testosterone Cardiovascular Trial in Men?
The TRAVERSE trial, published in the New England Journal of Medicine in 2023, evaluated cardiovascular safety in 5,246 men with hypogonadism and preexisting cardiovascular disease or elevated cardiovascular risk.
Participants received testosterone gel or placebo.
Major adverse cardiovascular events occurred in:
· 7.0% of the testosterone group.
· 7.3% of the placebo group.
The trial met its prespecified criterion for cardiovascular noninferiority for the primary outcome.
Although certain adverse events were more frequent in the testosterone group, including atrial fibrillation, acute kidney injury, and pulmonary embolism, the primary cardiovascular results did not demonstrate an increase in major adverse cardiovascular events.
Therefore, in February 2025, the FDA announed removal of the cardiovascular risk language from the boxed warning of testosterone products following this trial, while requiring updated blood-pressure warnings.
While men and women have different hormonal environments, and these findings cannot simply be transferred to women, the TRAVERSE trial demonstrates why prospective, dose-documented trials are essential when evaluating cardiovascular safety.
It also illustrates why an eightfold association from an observational database deserves careful scrutiny rather than immediate acceptance as a causal effect.
Testosterone Is Not Just a Male Hormone
One of the persistent misconceptions in women’s healthcare is that testosterone is primarily relevant to men.
Women naturally produce testosterone, and androgen receptors are distributed throughout multiple tissues, including the brain, muscles, skin, liver, kidneys, immune cells, cardiovascular system, bones, and yes, the reproductive system, just as estrogen receptors are overall.
Testosterone contributes to female sexual physiology and participates in complex interactions with estrogen and other hormonal pathways.
Yet the clinical conversation surrounding testosterone in women has often been narrowly focused on sexual desire.
The strongest randomized evidence supports treatment for appropriately selected postmenopausal women with hypoactive sexual desire disorder.
But in clinical practice, women frequently describe a much broader constellation of concerns.
They may experience declining energy, changes in muscle strength, diminished motivation, difficulty recovering from exercise, altered body composition, and a loss of their previous sense of vitality.
These symptoms can have multiple causes, and testosterone therapy has not been proven to treat all of them.
Still, the experiences of women who report meaningful improvements deserve thoughtful investigation rather than dismissal.
A lack of sufficient research into a potential benefit is not the same as evidence that the benefit does not exist.
This distinction is particularly important in women’s health, where research gaps have historically influenced treatment availability.
The Female Healthcare Disparity: Why Are We Still Having This Conversation?
This is perhaps the part of the discussion I feel most strongly about.
Women spend a substantial portion of their lives navigating hormonal transitions that can affect sleep, sexual health, mood, body composition, and overall quality of life.
Yet treatment options remain limited, and women often struggle to find clinicians who will investigate their symptoms comprehensively.
In the United States, there is still no FDA-approved testosterone product specifically indicated for women. Meanwhile, men have access to numerous approved testosterone products, including inections, gels, oral medications, nasal preparations and pellets. This disparity highlights the urgent need for greater investment in women’s hormonal health research and treatment development.
Clinicians who prescribe testosterone for women must therefore consider off-label treatment approaches.
Meanwhile, testosterone therapy for men has received considerably greater research attention, including large cardiovascular safety trials.
Women deserve similarly rigorous research.
We need studies examining different formulations, documented doses, achieved serum concentrations, treatment duration, clinical outcomes, and long-term cardiovascular health.
We also need research that addresses the outcomes women themselves identify as meaningful.
How do they feel?
Are they functioning better?
Has their sexual well-being improved?
Are they stronger, more active, or better able to participate in their lives?
And how do these potential benefits compare with treatment risks?
Quality of life is not a trivial outcome.
For a woman who has spent years feeling exhausted, disconnected, or unlike herself, meaningful improvement can be life-changing.
That experience deserves scientific attention.
Should Every Woman Be Treated to the Same Testosterone Level?
At Origin Medicine, I believe laboratory values are important, but they are only one part of a comprehensive clinical picture.
A laboratory reference range generally describes values found within a selected population.
It does not necessarily establish the optimal concentration for every woman, nor does it define a validated threshold at which cardiovascular harm begins.
Testosterone testing in women is also challenging because concentrations are relatively low, and results can be influenced by assay methods and sex hormone-binding globulin.
I believe it is important to consider a woman’s symptoms, medical history, functional status, treatment response, and laboratory findings together.
In my clinical practice, decisions are informed by clinical response, careful assessment, monitoring, and discussion of potential risks and uncertainties.
I recognize that this approach differs from current international consensus recommendations, which favor doses maintaining physiological premenopausal concentrations.
Those recommendations reflect the populations and regimens for which the strongest clinical trial evidence exists.
They do not establish a precise serum testosterone concentration at which cardiovascular harm begins.
However, they also do not establish the safety of sustained higher concentrations.
We need better dose-response research before making definitive claims about either the risks or benefits of higher-dose testosterone therapy in women.
Until then, individualized care requires both clinical judgment and transparency about the limitations of available evidence.
Are We Repeating the Women’s Health Initiative Experience?
In 2002, the Women’s Health Initiative (WHI) dramatically changed the conversation surrounding menopausal hormone therapy.
The trial identified important risks associated with specific hormone regimens, including oral conjugated equine estrogens combined with medroxyprogesterone acetate.
Those findings were real and clinically significant.
However, public messaging frequently failed to distinguish between formulations, routes of administration, age groups, and treatment timing.
For many women, the takeaway became:
Hormones are dangerous…
Subsequent research helped clarify that menopausal hormone therapy is considerably more nuanced.
The recent testosterone headlines raise a similar concern about communication.
There is, however, an important scientific distinction.
The WHI included randomized clinical trials, whereas the new testosterone findings came from a retrospective observational analysis.
These study designs cannot support the same conclusions about causation.
We should not dismiss legitimate safety findings, but neither should we allow preliminary associations to become definitive statements about harm.
When scientific communication creates unnecessary fear, women may avoid conversations about treatments that could improve their quality of life.
That is a consequence worth taking seriously.
My Perspective as a Clinician
I believe women have been underserved when it comes to hormonal health.
Too often, symptoms are normalized as an inevitable part of aging.
Women are told that fatigue, diminished sexual desire, changes in body composition, or a loss of vitality are simply things they must learn to accept.
I disagree.
Aging is inevitable. Accepting a diminished quality of life without investigating potential contributing factors should not be.
I have seen women experience profound improvements through individualized hormone care.
These experiences are why I believe this field deserves more research, not fewer treatment options.
At the same time, I recognize that meaningful clinical improvements do not automatically establish long-term safety, particularly when treatment involves doses outside those studied in randomized trials.
My responsibility is to consider both.
At Origin Medicine, our approach is comprehensive and individualized. We evaluate hormonal health alongside metabolic function, cardiovascular risk, nutrition, sleep, stress, and other factors that influence well-being.
We also believe that patients should participate actively in decisions about their care.
Women deserve informed choices—not fear-based decisions, automatic dismissal of their symptoms, or treatment protocols that ignore their individual circumstances.
The Bottom Line: Women Deserve Better Science and Better Care
The October 2026 testosterone study reported a striking association between documented testosterone treatment and cardiovascular diagnoses.
But the publicly available findings do not establish actual testosterone exposure, administered dose, achieved serum concentrations, or the individual components of the reported cardiovascular outcome.
Those limitations substantially weaken any attempt to interpret the association as proof of causation.
Meanwhile, prospective clinical trials and observational studies have not demonstrated a cardiovascular risk signal of comparable magnitude, although important limitations remain, particularly regarding long-term and higher-dose treatment.
There is currently insufficient evidence to conclude that testosterone therapy causes cardiovascular disease in women. There is also insufficient evidence to establish that every dose or formulation is cardiovascularly safe.
We should demand research capable of answering these questions rather than allowing preliminary findings to determine the entire conversation.
And we should recognize something equally important:
Women who experience meaningful improvements with hormone therapy deserve to have those experiences heard.
They deserve access to knowledgeable clinicians, individualized evaluations, honest discussions about uncertainty, and the opportunity to participate in decisions affecting their health.
At Origin Medicine, I believe healthcare should be about more than preventing disease.
It should also be about helping people live fully.
Women deserve more than reassurance that their symptoms are normal. They deserve to be heard, taken seriously, and offered thoughtful, evidence-informed options.
That is the standard of care we should be working toward.
Michelle Sandwisch, ARNP
Origin Medicine | Tacoma, Washington
This article is intended for educational purposes and does not replace individualized medical advice. Testosterone therapy should be considered through shared decision-making, including discussion of established benefits, potential adverse effects, cardiovascular risk factors, and uncertainties surrounding long-term safety.

